Cure My Disease

Don't miss your cure!

 Log in / Sign up

Single shot may shield fertility in women facing stem cell transplant

NCT ID NCT07552506

Not yet recruiting Disease control Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a single injection of goserelin, given just before a stem cell transplant, can help preserve ovarian function in women with severe aplastic anemia. The trial will enroll 132 women aged 14–50 and compare menstrual recovery rates six months after transplant between those who receive goserelin and those who do not. The goal is to reduce the risk of early menopause and protect fertility without affecting transplant success.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aplastic anemia idiopathic aplastic anemia ovarian dysfunction primary ovarian failure prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION APLASTIC ANAEMIA (AA) OVARIAN INSUFFICIENCY

Contacts and locations

Locations

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, 450000, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310000, China

  • The First People's Hospital of Yunnan Province

    Kunming, Yunnan, 650000, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430000, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.